C&EN Senior Editor Lisa Jarvis notes that until recent interest from big pharmaceutical companies, a small drug company in Cambridge, Mass. named Seaside Therapeutics was virtually the only company trying to develop drugs for autism and fragile X syndrome.
Diagnoses of autism and related conditions termed autism spectrum disorders have increased dramatically since the 1980s, for reasons not yet fully clear. They affect millions of people worldwide. Fragile X syndrome, the most common known genetic cause of autism, results from mutation in a single gene. Its symptoms range from learning impairment to mental retardation. The disease affects about 1 in 4,000 males and 1 in 6,000 to 8,000 females.
The article describes how Seaside, armed with funding from an anonymous wealthy family and new insights into the basic science behind these disorders, is making progress toward treating these much-neglected diseases. Two of the company's potential drugs show promise in clinical trials as treatments for Fragile X syndrome. One appears to improve the behavior of children with severe social impairments. On the heels of Seaside's encouraging results, big pharmaceutical companies that once showed little interest in tackling these diseases are now trying to develop their own new medications.
ARTICLE FOR IMMEDIATE RELEASE "Tackling Fragile X"
This story is available at http://pubs.acs.org/cen/business/88/8837bus3.html
Michael Bernstein | EurekAlert!
Molecular Force Sensors
20.09.2017 | Max-Planck-Institut für Biochemie
Foster tadpoles trigger parental instinct in poison frogs
20.09.2017 | Veterinärmedizinische Universität Wien
Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...
Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
20.09.2017 | Life Sciences
20.09.2017 | Power and Electrical Engineering
20.09.2017 | Physics and Astronomy